COSCIENS Biopharma Inc. Sales And Marketing Expense
COSCIENS Biopharma Inc. (CSCIF) reported Sales And Marketing Expense of $3.00 thousand for the 9-month period ending 2024-09-30, per its 6-K filed 2025-11-12.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:SalesAndMarketingExpense · last filed 2025-11-12
- COSCIENS Biopharma Inc. sales and marketing expense for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- COSCIENS Biopharma Inc. sales and marketing expense for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- COSCIENS Biopharma Inc. sales and marketing expense for the quarter ending 2024-03-31 was $3.00K.
- COSCIENS Biopharma Inc. sales and marketing expense for the quarter ending 2023-12-31 was $5.00K.
| Period end | Sales And Marketing Expense 3 month | Sales And Marketing Expense 6 month | Sales And Marketing Expense 9 month | Sales And Marketing Expense 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 derived: 6-K 9 month − 6-K 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $3.00K 6-K · filed 2025-11-12 | $8.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $0.00 derived: 6-K 6 month − 6-K 3 month · filed 2025-08-14 | $3.00K 6-K · filed 2025-08-14 | $8.00K derived: sum of 3 quarters · filed 2025-08-14 | $17.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $3.00K 6-K · filed 2025-05-13 | $8.00K derived: sum of 2 quarters · filed 2025-05-13 | $17.00K derived: sum of 3 quarters · filed 2025-05-13 | $27.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $5.00K derived: 20-F 12 month − 6-K 9 month · filed 2025-04-09 | $14.00K derived: sum of 2 quarters · filed 2025-04-09 | $24.00K derived: sum of 3 quarters · filed 2025-04-09 | $30.00K 20-F · filed 2025-04-09 |
| 2023-09-30 | $9.00K 6-K · filed 2024-11-12 | $19.00K derived: sum of 2 quarters · filed 2024-11-12 | $25.00K 6-K · filed 2024-11-12 | |
| 2023-06-30 | $10.00K 6-K · filed 2024-08-13 | $16.00K 6-K · filed 2024-08-13 | ||
| 2022-12-31 | $23.00K 20-F · filed 2025-04-09 |